IRCT20190210042676N13招募中2 期
Evaluation of safety and the effectiveness of Caffeine Plus Irox anti-hair loss line (serum and shampoo) produced by Iran Avandfar company In the prevention and treatment of androgenic hair loss
Iran Avandfar Company0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- Male
入选标准
- •Male aged 18-55 years
- •Good general health
- •Voluntary participation and sign the written informed consent
- •Hair Loss Status II, III, IV based on Norwood Scale
排除标准
- •Chronic active scalp disease other than hair loss
- •Using any prescribed drug or OTC for hair loss within the past 3 months
- •People with allergies to serum and shampoo ingredients
- •Any severe weight loss or strict diet therapy during the study
研究者
相似试验
招募中
2 期
Evaluation of safety and the effectiveness of Caffeine Plus Siseh anti-hair loss tonic and shampooIRCT20161207031288N8Sina Trading Company20
进行中（未招募）
1 期
An evaluation of the safety and effectiveness of combination therapy using the thiazolidinedione pioglitazone alongside insulin in type 2 diabetes mellitus.Type 2 Diabetes MellitusEUCTR2006-001982-41-GBBradford Teaching Hospitals NHS Foundation Trust40
进行中（未招募）
1 期
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients without PneumoniaCOVID-19 Patients without PneumoniaEUCTR2020-005214-18-LTVilnius University Hospital Santaros klinikos75
进行中（未招募）
1 期
Clinical trial of Favipiravir treatment of patients with COVID-19EUCTR2020-002728-35-HUHungarian Ministry of Innovation and Technology - Representative: Hecrin Consortium150
进行中（未招募）
1 期
An Investigation of the Efficacy and Safety of Favipiravir in COVID-19 Patients with Mild PneumoniaCOVID-19 Patients with Mild PneumoniaEUCTR2020-005128-12-LTVilnius University Hospital Santaros klinikos96